Cellectis vs Radiopharm Theranostics
CLLS and RADX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLLS and RADX compare
Cellectis grew revenue faster over the last twelve months (75.8% versus −23.8% for Radiopharm Theranostics).
Radiopharm Theranostics scores higher on the StockData Score (6 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLLS | RADX |
|---|---|---|
| Size and price | ||
| Share price | $1.18 | $0.760 |
| Change, 1 year | −67.7% | −83.8% |
| Change, 5 years | −86.8% | – |
| Beta (5Y) | 2.07 | 1.05 |
| Employees | 229 | 2 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 (better) | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 75.8% (better) | −23.8% |
| Revenue growth, 5Y average | 7.4% | – |
| Profitability | ||
| Gross margin | 100% (better) | 9.5% |
| Operating margin | −45.3% (better) | −2052% |
| Net margin | −92.7% | – |
| FCF margin | −57.2% | – |
| Return on equity | −97.8% | – |
| Return on invested capital | −122% | – |
| Financial health | ||
| Interest coverage | −0.6× (better) | −505.2× |
| Current ratio | – | 1.16 |
| Piotroski F-score | 3 | – |
| Ownership | ||
| Held by institutions | 9.4% | 1.4% |
| Held by insiders | 53.4% | 27.5% |
Go deeper
- CLLS stock overview
- CLLS income statement
- CLLS valuation and score
- RADX stock overview
- RADX income statement
- RADX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.